In May 2026, the Central Drugs Standards Organisation (CDSCO) released updated guidance on bioequivalence (BE) data requirements for Active Pharmaceutical Ingredients (APIs) and finished-dose formulations, marking the first substantive revision in three years. The new standard introduces stricter acceptance criteria for in-vivo BE studies, mandatory cross-referencing with WHO guidelines, and shortened timelines for resubmission of deficient dossiers.
For API manufacturers and contract research organisations, this shift signals a tightening regulatory environment ahead of India's anticipated alignment with ICH M9 standards (expected Q3 2026).
Market signals
CDSCO now mandates detailed population PK data, subject-level bioanalytical method validation records, and statistical sensitivity analyses in all BE submissions. Previously discretionary annexes are now mandatory, increasing dossier complexity by 20–30%.
CDSCO has shortened the deficiency-response window from 90 to 60 days, with a single extension allowed. Manufacturers who miss the deadline face automatic rejection and re-initiation of the review cycle—a costly reset.
The May circular explicitly references WHO TRS 1032 and ICH M9 draft outcomes, signalling India's intent to adopt global standards. APIs already approved under older CDSCO norms may require supplementary BE dossiers by end-2026.
This CDSCO revision materially impacts API and formulation approval timelines and dossier preparation costs. Businesses that file BE applications after June 2026 must comply immediately; those with pending or approved submissions may face supplementary review requests under the new standard. Vinayakam Consultants advises a proactive dossier audit of all in-flight applications, early engagement with bioanalytical CROs to pre-stage WHO-compliant method validation, and accelerated filing of any borderline submissions before the window closes. We guide manufacturers through CDSCO resubmission strategy, FAQ responses, and WHO guideline mapping to de-risk approval delays and budget overruns.
Your action checklist
- Audit all BE dossiers filed or under review with CDSCO since 2024; identify deficiencies against May 2026 guidance and file supplementary documentation proactively.
- Engage a CDSCO-familiar CRO to validate bioanalytical methods against WHO TRS 1032 standards and pre-stage population PK analysis before next submission.
- Map your API's approved indication and patient population against ICH M9 draft (available via CDSCO portal); assess whether supplementary in-vivo BE is needed.
- Document a 60-day response protocol for any CDSCO deficiency letter; assign ownership, pre-draft FAQs, and maintain a compliance dashboard to avoid rejection due to missed deadlines.
Frequently asked questions
CDSCO's May 2026 revision introduces stricter BE acceptance criteria, mandatory population PK data, subject-level bioanalytical validation records, and statistical sensitivity analyses. Previously discretionary annexes are now mandatory, increasing dossier complexity by 20–30%.
CDSCO has shortened the deficiency-response window from 90 to 60 days with only one extension allowed. Missing this deadline triggers automatic rejection and re-initiation of the review cycle.
CDSCO's May circular references WHO TRS 1032 and ICH M9, signalling India's adoption of global standards. APIs approved under older norms may require supplementary BE dossiers by end-2026.